Steven Zelenkofske

Steven Zelenkofske D.O. currently is Chief Medical Officer at SwanBio Therapeutics, a gene therapy company specializing in neurologic disease. Dr. Zelenkofske brings more than 20 years of industry development experience, most recently as Chief Medical Officer of Achillion Pharmaceuticals a clinical stage company specializing in complement inhibitors and at UniQure, a clinical stage gene therapy company. Previously he served as Chief Medical Officer of Regado Biosciences. He has also held leadership positions at Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. Dr. Zelenkofske has been responsible for multiple NDA filings and has worked across multiple therapeutic areas including cardiovascular, metabolic diseases, diabetes, nephrology, hematology, immunology and neurology.

Dr. Zelenkofske completed his residency training at Philadelphia College of Osteopathic Medicine, followed by fellowships in cardiology and electrophysiology at The Graduate Hospital, Philadelphia, and St. Luke’s Hospital, New York, respectively. He is a graduate of Emory University, where he also earned a Master of Science degree in immunopharmacology. He earned his Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine. He is a fellow of the American College of Cardiology, the American College of Chest Physicians, and the American College of Osteopathic Internists.